Special Issue

Advances in Plant Genetic Engineered Vaccines

Message from the Guest Editor

Several hurdles can limit vaccination, including a lack of knowledge about vaccinations, unreasonable fears about vaccine safety, a lack of transportation, cost, and the need for a cold chain and logistics of scheduling trained medical personnel for administration. Plant-produced vaccines have the potential to alleviate many of these hurdles. Plant-derived vaccines are produced by recombinant technology, in which the gene encoding the desired antigen protein is integrated into the plant genome.

This Special Issue focuses on **plant systems that can be used to improve vaccinations**. Plants can serve as factories for producing biopharmaceuticals and vaccines. The advantages of plant-based production platforms include easy scale-up, cost-effectiveness, and high safety, as plants are not hosts for human and animal pathogens. The objective of this issue is to highlight the **advantages and progress toward commercialization in various systems and discuss vaccination approaches**.

Keywords:

plant-produced vaccines

oral delivery

mucosal immunity

virus-like particles

Guest Editor

Dr. John Howard

Applied Biotechnology Institute, California Polytechnic Tech Park, San Luis Obispo, CA 93407, USA

Deadline for manuscript submissions

30 April 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/248327

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI